|
ES2863873T3
(es)
|
2016-05-18 |
2021-10-11 |
Mirati Therapeutics Inc |
Inhibidores de KRAS G12C
|
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
|
UA127968C2
(uk)
|
2017-05-22 |
2024-02-28 |
Емджен Інк. |
Інгібітори g12c kras і способи їх застосування
|
|
US10640504B2
(en)
|
2017-09-08 |
2020-05-05 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
CA3082579A1
(en)
|
2017-11-15 |
2019-05-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
US10597405B2
(en)
|
2017-12-08 |
2020-03-24 |
Astrazeneca Ab |
Chemical compounds
|
|
SG10202102462SA
(en)
*
|
2018-01-19 |
2021-04-29 |
Medshine Discovery Inc |
Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
*
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
BR112020020307A2
(pt)
*
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
EP3788053B1
(en)
|
2018-05-04 |
2024-07-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
WO2019232419A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
|
JP7369719B2
(ja)
*
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
|
CN112119075B
(zh)
*
|
2018-08-16 |
2024-03-12 |
豪夫迈·罗氏有限公司 |
稠环化合物
|
|
ES2961253T3
(es)
*
|
2018-08-31 |
2024-03-11 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
|
US12208099B2
(en)
|
2018-09-10 |
2025-01-28 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SMT202500028T1
(it)
*
|
2018-09-10 |
2025-03-12 |
Mirati Therapeutics Inc |
Terapie combinate
|
|
CA3112043A1
(en)
*
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
AU2019338207B2
(en)
*
|
2018-09-10 |
2025-01-02 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020055755A1
(en)
*
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
JP7337174B2
(ja)
|
2018-09-18 |
2023-09-01 |
ニカング セラピューティクス, インコーポレイテッド |
Srcホモロジー-2ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
|
|
CN114042070A
(zh)
|
2018-09-30 |
2022-02-15 |
凯瑞康宁生物工程(武汉)有限公司 |
作为神经元组胺受体-3拮抗剂的化合物及其用途
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
WO2020097537A2
(en)
*
|
2018-11-09 |
2020-05-14 |
Genentech, Inc. |
Fused ring compounds
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及びその使用方法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
US12377101B2
(en)
|
2018-12-05 |
2025-08-05 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
CN113382774A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和krasg12c抑制剂的药物组合
|
|
ES3010507T3
(en)
|
2019-03-05 |
2025-04-03 |
Astrazeneca Ab |
Fused tricyclic compounds useful as anticancer agents
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CA3141604A1
(en)
*
|
2019-05-20 |
2020-11-26 |
1200 Pharma Llc |
Kras g12c inhibitors and uses thereof
|
|
EP3972973A1
(en)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Solid state forms
|
|
US12252486B2
(en)
|
2019-05-21 |
2025-03-18 |
Amgen Inc. |
Solid state forms
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
CN113874374B
(zh)
*
|
2019-05-24 |
2024-12-27 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
CN118745177A
(zh)
*
|
2019-05-29 |
2024-10-08 |
上海翰森生物医药科技有限公司 |
含氮杂环类衍生物调节剂、其制备方法和应用
|
|
CN112047939B
(zh)
*
|
2019-06-06 |
2023-05-02 |
江苏先声药业有限公司 |
一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
|
|
WO2021000885A1
(zh)
*
|
2019-07-01 |
2021-01-07 |
江苏恒瑞医药股份有限公司 |
喹唑啉酮类衍生物、其制备方法及其在医药上的应用
|
|
CN112300153B
(zh)
*
|
2019-07-26 |
2023-06-13 |
博瑞生物医药(苏州)股份有限公司 |
一种杂环化合物、药物组合物和用途
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN112390797A
(zh)
*
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
CN112390796B
(zh)
*
|
2019-08-19 |
2023-06-27 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
CN112430234B
(zh)
*
|
2019-08-26 |
2023-04-28 |
信达生物制药(苏州)有限公司 |
一种新型kras g12c蛋白抑制剂及其制备方法和用途
|
|
CN114615981B
(zh)
|
2019-08-29 |
2024-04-12 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂
|
|
CN114616232B
(zh)
*
|
2019-09-06 |
2026-05-05 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
US20220402916A1
(en)
*
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
CN112538084B
(zh)
*
|
2019-09-23 |
2023-06-20 |
信达生物制药(苏州)有限公司 |
新颖的kras g12c蛋白抑制剂及其制备方法和用途
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
US20230257374A1
(en)
*
|
2019-10-10 |
2023-08-17 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel kras g12c protein inhibitor, preparation method therefor, and use thereof
|
|
CN112694475B
(zh)
*
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
MD4051678T2
(en)
|
2019-10-28 |
2026-07-31 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of the KRAS G12C mutant
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN121471132A
(zh)
|
2019-11-04 |
2026-02-06 |
锐新医药公司 |
Ras抑制剂
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
CN112778301A
(zh)
*
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
WO2021093758A1
(zh)
*
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
CN112824410A
(zh)
*
|
2019-11-21 |
2021-05-21 |
苏州泽璟生物制药股份有限公司 |
氮杂七元环类抑制剂及其制备方法和应用
|
|
CN114980976A
(zh)
*
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021106231A1
(en)
*
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
CN112979664B
(zh)
*
|
2019-12-02 |
2024-03-01 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
EP4015520B1
(en)
*
|
2019-12-02 |
2025-02-19 |
280 Bio, Inc. |
Oxygen-containing heterocyclic compound, preparation method and application thereof
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
CN112094269B
(zh)
*
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
US20230099858A1
(en)
*
|
2020-02-20 |
2023-03-30 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
|
CN115298174B
(zh)
*
|
2020-03-12 |
2023-11-03 |
德昇济医药(无锡)有限公司 |
嘧啶并杂环类化合物及其应用
|
|
TWI811656B
(zh)
*
|
2020-04-22 |
2023-08-11 |
大陸商德昇濟醫藥(無錫)有限公司 |
嘧啶并雜環類化合物及其應用
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
TW202144349A
(zh)
*
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為kras抑制劑的雜環化合物的製備及其應用方法
|
|
WO2021231526A1
(en)
*
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
CN113666923A
(zh)
*
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
CN113683616B
(zh)
*
|
2020-05-18 |
2025-12-30 |
广州百霆医药科技有限公司 |
Kras g12c突变蛋白抑制剂
|
|
CN116034106B
(zh)
|
2020-06-02 |
2025-11-04 |
勃林格殷格翰国际有限公司 |
用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
|
|
CN111646910A
(zh)
*
|
2020-06-15 |
2020-09-11 |
中国药科大学 |
一种盐酸达泊西汀消旋体的制备方法
|
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
|
JP2023531049A
(ja)
|
2020-06-24 |
2023-07-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sos1阻害剤及びkras g12c阻害剤を含む抗がん剤併用療法
|
|
CN113912608B
(zh)
*
|
2020-07-10 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
|
|
CN113980014B
(zh)
*
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
US12655160B2
(en)
|
2020-08-04 |
2026-06-16 |
Mirati Therapeutics, Inc. |
KRAS G12D inhibitors
|
|
EP4208261A1
(en)
|
2020-09-03 |
2023-07-12 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
WO2022052895A1
(zh)
|
2020-09-11 |
2022-03-17 |
南京明德新药研发有限公司 |
氮杂环丁烷取代化合物的晶型
|
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
|
EP4216951B1
(en)
*
|
2020-09-22 |
2026-04-01 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN116323624B
(zh)
*
|
2020-09-30 |
2026-07-10 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
AU2021362975A1
(en)
*
|
2020-10-14 |
2023-05-25 |
Ranok Therapeutics (Hangzhou) Co. Ltd. |
Methods and compositions for targeted protein degradation
|
|
JP7654071B2
(ja)
|
2020-10-20 |
2025-03-31 |
アムジエン・インコーポレーテツド |
複素環スピロ化合物及び使用方法
|
|
WO2022087375A1
(en)
*
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel heterocyclic compounds
|
|
WO2022087371A1
(en)
*
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel bicyclic compounds
|
|
WO2022105855A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
KR102503336B1
(ko)
|
2020-11-23 |
2023-02-23 |
동의대학교 산학협력단 |
음성지원이 가능한 반려동물의 배변 처리 패드
|
|
WO2022109485A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
CN116829151A
(zh)
*
|
2020-12-15 |
2023-09-29 |
米拉蒂治疗股份有限公司 |
氮杂喹唑啉泛KRas抑制剂
|
|
EP4262807A4
(en)
|
2020-12-15 |
2025-04-23 |
Mirati Therapeutics, Inc. |
Azachinazoline pan-KRAS inhibitors
|
|
WO2022133038A1
(en)
*
|
2020-12-16 |
2022-06-23 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
AU2021409561A1
(en)
|
2020-12-22 |
2023-07-06 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
TWI793999B
(zh)
*
|
2021-02-01 |
2023-02-21 |
大陸商南京明德新藥研發有限公司 |
嘧啶並吡喃化合物
|
|
CN116600808B
(zh)
*
|
2021-02-09 |
2024-10-22 |
苏州阿尔脉生物科技有限公司 |
一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
CN116964057A
(zh)
*
|
2021-03-10 |
2023-10-27 |
贝达医药公司 |
作为kras抑制剂的吡啶并嘧啶衍生物
|
|
WO2022194192A1
(zh)
*
|
2021-03-18 |
2022-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
MX2023011856A
(es)
|
2021-04-08 |
2024-01-08 |
Mirati Therapeutics Inc |
Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
|
|
JP2024514127A
(ja)
|
2021-04-09 |
2024-03-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗がん剤療法
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
EP4322945A4
(en)
*
|
2021-04-16 |
2025-07-16 |
Mirati Therapeutics Inc |
KRAS G12C INHIBITORS
|
|
US20240239788A1
(en)
*
|
2021-04-16 |
2024-07-18 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras g12d mutant
|
|
WO2022223020A1
(zh)
*
|
2021-04-23 |
2022-10-27 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
CN117203207A
(zh)
*
|
2021-04-30 |
2023-12-08 |
江苏恒瑞医药股份有限公司 |
桥环类化合物、其制备方法及其在医药上的应用
|
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
JP2024521788A
(ja)
|
2021-05-27 |
2024-06-04 |
ミラティ セラピューティクス, インコーポレイテッド |
併用療法
|
|
CN117769554A
(zh)
*
|
2021-05-28 |
2024-03-26 |
大鹏药品工业株式会社 |
Kras突变蛋白的小分子抑制剂
|
|
WO2022261210A1
(en)
*
|
2021-06-08 |
2022-12-15 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
|
|
US20250145639A1
(en)
*
|
2021-06-23 |
2025-05-08 |
Newave Pharmaceutical Inc. |
Mutant kras modulators and uses thereof
|
|
KR20240024928A
(ko)
|
2021-06-23 |
2024-02-26 |
노파르티스 아게 |
Kras 돌연변이 단백질의 억제제로서의 피라졸릴 유도체
|
|
WO2023280026A1
(zh)
*
|
2021-07-05 |
2023-01-12 |
四川科伦博泰生物医药股份有限公司 |
杂芳环化合物、其制备方法及用途
|
|
WO2023283213A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
CN117157292A
(zh)
*
|
2021-07-16 |
2023-12-01 |
苏州赞荣医药科技有限公司 |
Kras g12d抑制剂和其用途
|
|
EP4378478A4
(en)
|
2021-07-27 |
2025-11-12 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
|
CN116143806A
(zh)
*
|
2021-08-08 |
2023-05-23 |
上海凌达生物医药有限公司 |
一类含氮杂环类化合物、制备方法和用途
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
US20240374571A1
(en)
|
2021-09-01 |
2024-11-14 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
EP4389751A1
(en)
*
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CN117222646A
(zh)
*
|
2021-09-16 |
2023-12-12 |
苏州赞荣医药科技有限公司 |
Kras g12c抑制剂和其用途
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023057985A1
(en)
*
|
2021-10-08 |
2023-04-13 |
Vrise Therapeutics, Inc. |
Small molecules for treatement of cancer
|
|
KR20240089594A
(ko)
|
2021-10-22 |
2024-06-20 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
질소 함유 테트라시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용
|
|
KR20240114793A
(ko)
*
|
2021-11-05 |
2024-07-24 |
프론티어 메디슨즈 코포레이션 |
Kras g12c 억제제
|
|
CR20240233A
(es)
|
2021-12-01 |
2024-07-17 |
Univ Vanderbilt |
Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
|
|
CN117940436A
(zh)
*
|
2021-12-02 |
2024-04-26 |
上海和誉生物医药科技有限公司 |
一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用
|
|
EP4442686A4
(en)
*
|
2021-12-02 |
2025-10-22 |
Abbisko Therapeutics Co Ltd |
KRAS INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL USE
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
CN118339153A
(zh)
|
2021-12-22 |
2024-07-12 |
勃林格殷格翰国际有限公司 |
用于治疗癌症的杂芳族化合物
|
|
AU2022421224A1
(en)
|
2021-12-22 |
2024-06-20 |
The Regents Of The University Of California |
Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
|
|
CN116410145A
(zh)
*
|
2021-12-29 |
2023-07-11 |
上海泓博智源医药股份有限公司 |
一种mrtx849中间体的制备方法
|
|
CN118434740A
(zh)
*
|
2021-12-31 |
2024-08-02 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
WO2023137223A1
(en)
*
|
2022-01-17 |
2023-07-20 |
Newave Pharmaceutical Inc. |
Pan-kras inhibitors and uses thereof
|
|
WO2023138583A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
US20250154170A1
(en)
|
2022-02-10 |
2025-05-15 |
Bayer Aktiengesellschaft |
Fused pyrimidines as kras inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
CN116891514A
(zh)
*
|
2022-04-06 |
2023-10-17 |
润佳(苏州)医药科技有限公司 |
一种双官能化合物及其用途
|
|
KR20240167846A
(ko)
|
2022-03-28 |
2024-11-28 |
니캉 테라퓨틱스 인코포레이티드 |
사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체
|
|
EP4504203A1
(en)
|
2022-04-04 |
2025-02-12 |
Sanofi |
Therapeutic combination of kras g12c inhibitor and tead inhibitor
|
|
CN116891488B
(zh)
*
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
US20230365595A1
(en)
*
|
2022-05-13 |
2023-11-16 |
Ranok Therapeutics (Hangzhou) Co. Ltd. |
Inhibitors of kras(g12d)
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
CN119790053A
(zh)
|
2022-06-08 |
2025-04-08 |
霖康疗法公司 |
作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
US20250368649A1
(en)
*
|
2022-06-14 |
2025-12-04 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
WO2023244615A1
(en)
*
|
2022-06-15 |
2023-12-21 |
Mirati Therapeutics, Inc. |
Azaquinazoline pan-kras inhibitors
|
|
GB202212641D0
(en)
|
2022-08-31 |
2022-10-12 |
Jazz Pharmaceuticals Ireland Ltd |
Novel compounds
|
|
AU2023353561A1
(en)
*
|
2022-09-28 |
2025-05-08 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US20260137665A1
(en)
|
2022-10-11 |
2026-05-21 |
Aadi Bioscience, Inc. |
Combination therapies for the treatment of cancer
|
|
AU2023377064A1
(en)
|
2022-11-09 |
2025-05-22 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|
|
IL320316A
(en)
|
2022-11-11 |
2025-06-01 |
Nikang Therapeutics Inc |
Bifunctional compounds containing pyrimidine derivatives with substitutions at positions 2 and 5, for degradation of cyclin-dependent kinase 2 (CDK2) via the ubiquitin-proteasome pathway
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
CN121487951A
(zh)
|
2023-04-07 |
2026-02-06 |
锐新医药公司 |
大环ras抑制剂
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
EP4695261A1
(en)
|
2023-04-14 |
2026-02-18 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
KR20240168510A
(ko)
*
|
2023-05-22 |
2024-12-02 |
주식회사 이노파마스크린 |
Kras g12d 및 g12v 돌연변이 표적 화합물 및 그 용도
|
|
CN116640104B
(zh)
*
|
2023-05-24 |
2024-04-02 |
杭州科耀医药科技有限公司 |
一种替洛利生的工业合成方法
|
|
JP2026520494A
(ja)
|
2023-05-31 |
2026-06-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がん処置の応答性を予測するためのバイオマーカーとしてのサバイビン
|
|
JPWO2024248123A1
(enExample)
|
2023-06-02 |
2024-12-05 |
|
|
|
CN116675690B
(zh)
*
|
2023-06-02 |
2026-03-27 |
北京康立生医药技术开发有限公司 |
一种肺癌治疗药物的制备方法
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
KR20260104082A
(ko)
|
2023-09-29 |
2026-07-03 |
디3 바이오 (우씨) 컴퍼니, 리미티드 |
암의 치료에 사용하기 위한 wx-001 또는 그의 유도체와 kras g12c 억제제의 조합물
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
CN122249438A
(zh)
|
2023-11-27 |
2026-06-19 |
霖康疗法公司 |
用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2和细胞周期蛋白依赖性激酶4的含有2,5-取代的嘧啶衍生物的双功能化合物
|
|
CN122341597A
(zh)
|
2023-12-02 |
2026-07-03 |
霖康疗法公司 |
用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有2,5-取代的嘧啶衍生物的双功能化合物
|
|
IL330174A
(en)
|
2023-12-20 |
2026-08-01 |
Boehringer Ingelheim Int Gmbh |
Combination cancer treatment using zongratinib and KRAS G12C inhibitor
|
|
CN122459678A
(zh)
|
2023-12-29 |
2026-07-24 |
百时美施贵宝公司 |
KRAS抑制剂与Treg耗竭剂的组合疗法
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026003808A1
(en)
|
2024-06-28 |
2026-01-02 |
Assia Chemical Industries Ltd. |
Solid state form of adagrasib and process for preparation
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
TW202615038A
(zh)
|
2024-08-07 |
2026-04-16 |
美商太斯萊特醫藥美國有限責任公司 |
包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|